Technical review by the ESPGHAN Special Interest Group on Gut Microbiota and Modifications on the health outcomes of infant formula supplemented with manufactured human milk oligosaccharides
Journal of Pediatric Gastroenterology and Nutrition · 2026-01 · 82 (1) · 225-234
DOI: 10.1002/jpn3.70032 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, online erschienen am 24.03.2025. Verfasst von Iva Hojsak und 7 weiteren Autor:innen. Beteiligte Einrichtung: Children's Hospital Zagreb, University of Zagreb Medical School, Zagreb, Croatia. Hauptthemen laut MEDLINE: Dietary Supplements, Gastrointestinal Microbiome, Infant Formula, Milk, Human. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: None.
Abstract (Originalsprache)
This technical review, one of five developed by the European Society for Pediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) special interest group (SIG) on gut microbiota and modifications (GMM), supports the creation of a position paper on the use of biotic‐supplemented formulas, including those containing human milk oligosaccharides (HMOs) produced through chemical synthesis or microbial biotechnology. Though these oligosaccharides are identical to the HMOs found in human milk, they do not originate from it. Therefore, we used human‐identical milk oligosaccharides (HiMOs). This review focuses on the clinical outcomes related to the supplementation of infant formulas with these HiMOs. The ESPGHAN SIG‐GMM conducted a systematic review to evaluate the clinical outcomes of HiMO‐supplemented infant formulas in healthy infants (0–12 months) published before 2024. Six RCTs and two mechanistic substudies met the inclusion criteria and investigated different combinations of HiMOs added to the formula. The HiMOs studied so far show no difference compared to the control formula in outcomes such as: anthropometric data, regurgitation‐related symptoms, crying, fussiness, or colic. A specific combination of five HMO‐analogues (2′fucosyllactose [FL], 3‐FL, lacto‐N‐tetraose [LNT], 3′‐sialyllactose [SL], and 6′‐SL) suggest a softer stool consistency and more frequent defecation in presumable healthy infants, but these studies also used the highest amount of HiMOs; however, the clinical relevance of this finding remains uncertain. Regarding infection prevention, no clear conclusion can be drawn. There was no difference in tolerability and no safety concerns were raised with the HiMO studied so far. This technical report serves as the background for formulating recommendations on the use of HiMOs‐supplemented infant formula in healthy infants studied so far.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Children's Hospital Zagreb, University of Zagreb Medical School, Zagreb, Croatia.
- Department of Pediatrics, Eskisehir Osmangazi University Faculty of Medicine, Eskisehir, Turkiye.
- Department of Pediatrics - Neonatology, Emma Children's Hospital, Amsterdam UMC, Amsterdam Reproduction & Development Research Institute, University of Amsterdam, Amsterdam, The Netherlands.
- Department of Clinical Sciences, Paediatrics, Umeå University, Umeå, Sweden.
- Department of Neonatology, Kepler University Hospital, Linz, Austria.
- Department of Paediatrics, The Medical University of Warsaw, Warsaw, Poland.
ORCID-Profile: Ener C Dinleyici
Förderung
- None
Zitieren
APA
Hojsak, I., Dinleyici, E. C., van den Akker, C. H. P., Domellöf, M., Haiden, N., Szajewska, H., Vandenplas, Y., & ESPGHAN Special Interest Group on Gut Microbiota and Modifications (2026). Technical review by the ESPGHAN Special Interest Group on Gut Microbiota and Modifications on the health outcomes of infant formula supplemented with manufactured human milk oligosaccharides. Journal of Pediatric Gastroenterology and Nutrition, 82(1), 225-234. https://doi.org/10.1002/jpn3.70032
Vancouver
Hojsak I, Dinleyici EC, van den Akker CHP, Domellöf M, Haiden N, Szajewska H, et al. Technical review by the ESPGHAN Special Interest Group on Gut Microbiota and Modifications on the health outcomes of infant formula supplemented with manufactured human milk oligosaccharides. Journal of Pediatric Gastroenterology and Nutrition. 2026;82(1):225-234. doi:10.1002/jpn3.70032
BibTeX
@article{Hojsak2026,
author = {Hojsak, Iva and Dinleyici, Ener C and van den Akker, Chris H P and Domellöf, Magnus and Haiden, Nadja and Szajewska, Hania and Vandenplas, Yvan and ESPGHAN Special Interest Group on Gut Microbiota and Modifications, ESPGHAN Special Interest Group on Gut Microbiota and Modifications},
title = {Technical review by the ESPGHAN Special Interest Group on Gut Microbiota and Modifications on the health outcomes of infant formula supplemented with manufactured human milk oligosaccharides},
journal = {Journal of Pediatric Gastroenterology and Nutrition},
year = {2026},
volume = {82},
number = {1},
pages = {225--234},
doi = {10.1002/jpn3.70032}
}
EUVIMED